Digital Portfolio Selections

Bridget Allen
BridgetAllen915@gmail.com
DuPont Intexar

A responsive site to educate about DuPont’s “smart fabric” Intexar solutions

Audience: buyers, investors

Designed and developed mobile-first
THE INTEKAR SOLUTION.

Ergonomic design provides heat technology solutions that are comfortable and safe. Our technology can provide all-day comfort and is designed to keep you warm when the temperature drops. -

THE FUTURE OF HEAT TECHNOLOGY.

• COMFORTABLE
• BREATHABLE
• DURABLE
• WASHABLE
• ASSURANCE
• REGULATED

Heat applications:

OUTDOOR
Datawears
- Stylish, lightweight, breathable, and flexible for all outdoor activities
- Made of high-quality materials that keep you warm and comfortable

INDUSTRY
Professionals
- Suitable for all environments
- Protects from extreme heat and cold

Next starts now.

Contact us for more information on how INTEKAR HEAT can transform your experience.
HCP Website

A responsive site for a new brand launch
Audience: healthcare providers
Designed and developed mobile-first
Important Safety Information

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exercitation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros et accumsan et iusto odio dignissim qui blandit praesent luptatum zzril delenit augue duis dolore te feugait nulla facilisi. Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exercitation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exercitation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros et accumsan et iusto odio dignissim qui blandit praesent luptatum zzril delenit augue duis dolore te feugait nulla facilisi. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exercitation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.
The Need for New Antibiotics

Introducing XENLETA Efficacy

Patient Profiles

Safety

Dosing

Support

Important Safety Information

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exercitation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros et accumsan et iusto odio dignissim qui blandit praesent luptatum zzril delenit augue duis dolore te feugait nulla facilisi.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exercitation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exercitation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.
Important Safety Information

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exercitation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisi. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliqua erat volupat. Ut wisi enim ad minim veniam, quis nostrud exercitation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliqua erat volupat. Ut wisi enim ad minim veniam, quis nostrud exercitation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.
The Need for New Antibiotics

Introducing XENLETA

Efficacy

Patient Profiles

Safety

Dosing

Support

Important Safety Information

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exercitation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros et accumsan et iusto odio dignissim qui blandit praesent luptatum zzril delenit augue duis dolore te feugait nulla facilisi.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exercitation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros et accumsan et iusto odio dignissim qui blandit praesent luptatum zzril delenit augue duis dolore te feugait nulla facilisi.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exercitation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros et accumsan et iusto odio dignissim qui blandit praesent luptatum zzril delenit augue duis dolore te feugait nulla facilisi.

MORE IMPORTANT SAFETY INFORMATION

Title of Video
Important Safety Information

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exercitation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros et accumsan et iusto odio dignissim qui blandit praesent luptatum zzril delenit augue duis dolore te feugait nulla facilisi.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exercitation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exercitation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.
Important Safety Information

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exercitation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugait nulla facilisi. Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exercitation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exercitation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugait nulla facilisi. Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exercitation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exercitation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugait nulla facilisi. Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exercitation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exercitation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugait nulla facilisi. Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exercitation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.
For the treatment of adults with community-acquired bacterial pneumonia

The Total CABP Package

**XENLETA**: the first and only oral and IV pleuromutilin empiric antibiotic that acts against the pathogens that commonly cause CABP.¹²

- Demonstrated monotherapy efficacy
  XENLETA achieved early and effective clinical

- Convenient oral or IV dosing flexibility
  Start patients with IV, then switch to oral—or

- A novel mechanism of action
  A pleuromutilin with a low propensity for

**Indication and Important Safety Information**

**Indication**

XENLETA is a pleuromutilin antibacterial indicated for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: *Streptococcus pneumoniae*, *Staphylococcus aureus* (methicillin-susceptible isolates), *Haemophilus influenzae*, *Legionella pneumophila*, *Mycoplasma pneumoniae*, and *Chlamydia pneumoniae*.

**Usage**


For the treatment of adults with community-acquired bacterial pneumonia

The Total CABP Package

XENLETA: the first and only oral and IV pleuromutilin empiric antibiotic that acts against the pathogens that commonly cause CABP.1,2

- Demonstrated monotherapy efficacy
- XENLETA achieved early and effective clinical

- Convenient oral or IV dosing flexibility
- Start patients with IV, then switch to oral—or

- A novel mechanism of action
- A pleuromutilin with a low propensity for...

Indication and Important Safety Information

Indication

XENLETA is a pleuromutilin antibacterial indicated for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumoniae, Mycoplasma pneumoniae, and Chlamydia pneumoniae.

Usage
Indication

XENLETA is a pleuromutilin antibacterial indicated for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydia pneumoniae.

Usage

To reduce the development of drug-resistant bacteria and maintain the effectiveness of XENLETA and other antibacterial drugs, XENLETA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

Important Safety Information

CONTRAINdications

XENLETA is contraindicated in patients with known hypersensitivity to XENLETA or pleuromutilins.

XENLETA tablets are contraindicated for use with CYP3A4 substrates that prolong the QT interval.

WARNINGS AND PRECAUTIONS

XENLETA has the potential to prolong the QT interval. Avoid XENLETA in patients with known QT prolongation, ventricular arrhythmias, and patients receiving drugs that may prolong the QT interval.

Based on animal studies, XENLETA may cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception.

Diarrhea associated with diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including XENLETA, with severity ranging from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs.

ADVERSE REACTIONS

The most common adverse reactions (≥2%) for XENLETA injection are administration site reactions, hepatic enzyme elevation, nausea, hypokalemia, insomnia, and headache.

XENLETA Tablets are diarrhea, nausea, vomiting, and hepatic enzyme elevation.

USE IN SPECIFIC POPULATIONS

In patients with severe hepatic impairment, reduce the dosage of XENLETA injection to 175 mg infused over 60 minutes every 24 hours. XENLETA Tablets are not recommended in patients with moderate or severe hepatic impairment due to insufficient information to provide dosing recommendations.

Avoid XENLETA injection and Tablets with concomitant strong or moderate CYP3A or P-gp inducers. Monitor for reduced efficacy of XENLETA.

Avoid XENLETA Tablets with strong CYP3A or P-gp inhibitors.

Monitor for adverse reactions of sensitive CYP3A substrates administered with XENLETA Tablets.

XENLETA has not been studied in pregnant women. Verify pregnancy status in females prior to initiating XENLETA and advise females to use contraception during treatment and for 2 days after the final dose. Lactating women should pump and discard milk for the duration of treatment with XENLETA and for 2 days after the final dose.

To report SUSPECTED ADVERSE REACTIONS, or administration during pregnancy, contact Nabiriva Therapeutics US, Inc. at 1-855-SNAambio or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Full Prescribing Information for XENLETA.

References


All trademarks are the property of Nabiriva Therapeutics Ireland DAC

Distributed by Nabiriva Therapeutics US, Inc.
© 2019 Nabiriva Therapeutics US, Inc.
PM-45-LEF-0077 SEP 2019
XENLETA is a systemic, empiric pleuromutilin antibiotic with activity against specific Gram-positive, Gram-negative, and other respiratory bacteria.\(^1\)

- **Novel mechanism of action (MoA) as a pleuromutilin with a chemical structure distinct from existing classes in CABP\(^1\)**
- **Low propensity for resistance due to unique ribosomal binding via multiple interactions\(^2\)**
- **Some isolates resistant to β-lactams, macrolides, quinolones, tetracyclines, and other treatments may be susceptible to XENLETA\(^1\)**

**Indication**
XENLETA is a pleuromutilin antibacterial indicated for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus [methicillin-susceptible isolates], Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydia pneumoniae.

**Usage**
To reduce the development of drug-resistant bacteria and maintain the effectiveness of XENLETA and other antibacterial drugs, XENLETA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

**Important Safety Information**

**Contraindications**
XENLETA is contraindicated in patients with known hypersensitivity to XENLETA or pleuromutilins.

**Warnings and Precautions**
XENLETA has the potential to prolong the QT interval. Avoid XENLETA in patients with known QT prolongation, ventricular arrhythmias, and patients receiving drugs that may prolong the QT interval. Based on animal studies, XENLETA may cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception.

**Adverse Reactions**
The most common adverse reactions (≥2% for at least one XENLETA injection) are administration site reactions, hepatic enzyme elevation, nausea, hypokalemia, insomnia, and headache. A common adverse reaction (4% or more) is diarrhea.

**Use in Specific Populations**
In patients with severe hepatic impairment, reduce the dosage of XENLETA injection to 160 mg infused over 90 minutes every 24 hours. XENLETA Tablets are not recommended in patients with moderate or severe hepatic impairment due to insufficient information to provide dosing recommendations. Avoid XENLETA injection and Tablets with concomitant strong or moderate CYP3A or P-gp inducers. Monitor for reduced efficacy of XENLETA.

**Adverse Reactions**
XENLETA Tablets with strong CYP3A or P-gp inhibitors.

**Monitor for adverse reactions of sensitive CYP3A substrates administered with XENLETA Tablets.**

**XENLETA has not been studied in pregnant women. Verify pregnancy status in females prior to initiating XENLETA and advise females to use contraception during treatment and for 2 days after the final dose. Lactating women should pump and discard milk for the duration of treatment with XENLETA and for 2 days after the final dose.**

**To report SUSPECTED ADVERSE REACTIONS, or administration during pregnancy, contact Nabiriva Therapeutics US, Inc. at 1-855-SNABRIVA or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.**

Please see Full Prescribing Information for XENLETA.

**References**

All trademarks are the property of Nabiriva Therapeutics Ireland DAC.
Distributed by Nabiriva Therapeutics US, Inc.
© 2018 Nabiriva Therapeutics US, Inc.
PM-US-LET-0077 SEP 2019
Y-mAbs Therapeutics

A responsive site for an up-and-coming therapeutics company
Audience: caregivers, medical professionals (partners), investors
Designed and developed mobile-first
EXISTING DESIGN
Press Releases

- Y-mAbs Therapeutics To Present At The H.C. Wainwright Global Life Sciences Conference in London
- Y-mAbs Announces 2018 Financial Results and Corporate Development Highlights
- Y-mAbs Therapeutics To Present At Cowen’s 39th Annual Health Care Conference
- Y-mAbs Therapeutics to Present at PEGS Boston
- Y-mAbs Therapeutics To Present At 37th Annual J.P. Morgan Healthcare Conference
- Y-mAbs Announces Appointment of Gérard Ber to its Board of Directors and Planned Departure of Michael Buschle
- Y-mAbs Therapeutics Announces FDA Clearance of IND for its Bispecific GD2 Antibody
- Y-mAbs Announces Third Quarter 2018 Financial Results and Recent Corporate Developments
- Bispecific GD2 Antibody In Vivo Data to be Presented at ASH
- Naxitamab Receives Positive Opinion for Orphan Medicinal Product Designation Approval in the EU

Clinical Pipeline Highlights

<table>
<thead>
<tr>
<th>Product Candidate</th>
<th>Target</th>
<th>Load</th>
<th>Indication/Treatment</th>
<th>Development Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pre-Clinical</td>
</tr>
<tr>
<td>Naked</td>
<td>GD2</td>
<td>Naked</td>
<td>Relapsed/Refractory High-Risk Neuroblastoma (Pediatric)</td>
<td>Ongoing Phase II trial</td>
</tr>
<tr>
<td>Naked</td>
<td></td>
<td>Naked</td>
<td>Relapsed/Refractory High-Risk Neuroblastoma (Pediatric)</td>
<td>Ongoing Phase II trial</td>
</tr>
<tr>
<td>Naked</td>
<td></td>
<td>Naked</td>
<td>(Front-Line) High-Risk Neuroblastoma (Pediatric)</td>
<td>Ongoing Phase II trial</td>
</tr>
<tr>
<td>Naked</td>
<td></td>
<td>Naked</td>
<td>Relapsed (Second-Line) Osteosarcoma</td>
<td>Ongoing Phase II trial</td>
</tr>
<tr>
<td>Naked</td>
<td></td>
<td>Naked</td>
<td>Chemoinmunotherapy for Relapsed/Refractory High-Risk Neuroblastoma</td>
<td>Ongoing Phase III</td>
</tr>
<tr>
<td>131I</td>
<td>B7-H3</td>
<td></td>
<td>CNS/Leptomeningeal Metastases from Neuroblastoma (Pediatric)</td>
<td>Ongoing Phase II trial</td>
</tr>
<tr>
<td>131I</td>
<td>B7-H3</td>
<td></td>
<td>Intrathecal Immunotherapy for CNS/Leptomeningeal Metastases</td>
<td>Ongoing Phase II trial</td>
</tr>
<tr>
<td>124I</td>
<td></td>
<td></td>
<td>Diffuse Intrinsic Pontine Glioma (Pediatric)</td>
<td>Ongoing Phase II trial</td>
</tr>
<tr>
<td>131I</td>
<td></td>
<td></td>
<td>Desmoplastic Small Round Cell Tumor (Pediatric)</td>
<td>Ongoing Phase II trial</td>
</tr>
<tr>
<td>Omburtamab-DTPA</td>
<td>B7-H3</td>
<td></td>
<td>B7-H3 Positive CNS/Leptomeningeal Solid Tumors</td>
<td>Ongoing Phase II trial</td>
</tr>
<tr>
<td>huB7-H3</td>
<td>B7-H3</td>
<td>TBD</td>
<td>Systemic Solid Tumors (Adult) (Third-Line)</td>
<td>Ongoing Phase II trial</td>
</tr>
<tr>
<td>huGD2-8sAb</td>
<td>GD2xCD3</td>
<td>Naked</td>
<td>Refractory GD2-Positive Solid Tumors</td>
<td>Ongoing Phase II trial</td>
</tr>
<tr>
<td>huCD33-8sAb</td>
<td>CD33xCD3</td>
<td>Naked</td>
<td>Hematological Cancers Expressing CD33</td>
<td>Ongoing Phase II trial</td>
</tr>
</tbody>
</table>

Overview

Y-mAbs Therapeutics, Inc (Y-mAbs) is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets based on a range of technologies licensed from Memorial Sloan Kettering Cancer Center ("MSK") under an exclusive worldwide license and research collaboration agreement. Y-mAbs applies its world-class antibody capabilities to create life-changing immunotherapies for cancer patients of all ages. Y-mAbs’ innovative product candidates leverage its extensive drug development capabilities and its proprietary protein technology platform – MULTI TAG™.

Mission

Our Mission is to become the world leader in developing better and safer antibody based pediatric oncology products addressing clear unmet medical needs. We will expand into certain adult cancer indications and advance these in collaboration with partners.

Company Highlights

- Y-mAbs is a clinical stage biotechnology company specialized in developing novel antibody therapeutics to treat cancer
- Memorial Sloan Kettering Cancer Center, the world’s largest and oldest private cancer institution, is Y-mAbs’ scientific collaboration partner and shareholder
- From MSK, Y-mAbs has exclusive global rights to two clinical stage antibody programs with a strong validated clinical safety profile, treating more than 1,000 neuroblastoma patients. These programs are today used as “standard-of-care” treatment for patients at Memorial Sloan Kettering Cancer Center
- Further, Y-mAbs has licensed a protein Multimerization Technology Platform - MULTI TAG™, incubated and developed at MSK to further enhance the therapeutic effect of antibodies
- Several ongoing clinical trials significantly improve survival rates for critical unmet medical needs among cancer patients
- Y-mAbs has a management team with proven track record and antibody drug development experience as well as expertise in running leading public biopharmaceutical companies

Y-mAbs Therapeutics, Inc

USA
Y-mAbs Therapeutics, Inc
230 Park Avenue, Suite 3550
New York, NY 10169
USA
Telephone: +1 646 885 8505
E-mail: info@ymabs.com

EU
Y-mAbs Therapeutics A/S
Agorn All 11, ground floor
2970 Hoersholm
Denmark
Tlf.: +45 70 26 14 14
E-mail: info@ymabs.com
Proposed Design

(HOMEPAGE - Desktop & Mobile)
About the Y-mAbs development pipeline of therapies

Y-mAbs Therapeutics has an expanding pipeline that features two investigational antibodies, rocamabulin and omburtamab. Both have been recognized by the FDA as they were recently granted breakthrough therapy designation to expedite the development and review of their drugs.

The safety and efficacy of these products have not been established by health authorities. These products are investigational and have not been approved in the US or globally.

Broad and Advanced Clinical Product Development Pipeline

<table>
<thead>
<tr>
<th>Study</th>
<th>Anticipated Treatment</th>
<th>Phase 1/2 Results</th>
<th>Phase 3 Update</th>
<th>Next Anticipated Milestone</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03459752</td>
<td>Bacteroidetes High Risk Neuroblastoma (Pediatric)</td>
<td>Ongoing Phase 1.5</td>
<td>-</td>
<td>Full Phase 3 Submission</td>
</tr>
<tr>
<td>NCT03664614</td>
<td>Enterobacteriaceae High Risk Neuroblastoma (Pediatric)</td>
<td>Ongoing Phase 1-2</td>
<td>-</td>
<td>Full Phase 3 Submission</td>
</tr>
<tr>
<td>NCT03664615</td>
<td>Enterobacteriaceae High Risk Neuroblastoma (Pediatric)</td>
<td>Ongoing Phase 1-2</td>
<td>-</td>
<td>Full Phase 3 Submission</td>
</tr>
<tr>
<td>NCT03664616</td>
<td>Bacillus Subtilis Small Round Cell Tumor (Pediatric)</td>
<td>Ongoing Phase 2</td>
<td>-</td>
<td>Full Phase 3 Submission</td>
</tr>
</tbody>
</table>

Preclinical and Research Pipeline

<table>
<thead>
<tr>
<th>Product Candidate</th>
<th>Target</th>
<th>Anticipated Treatment</th>
<th>Next Anticipated Milestone</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03459752.c01</td>
<td>Bacteroidetes High Risk Neuroblastoma (Pediatric)</td>
<td>Ongoing Phase 1.5</td>
<td>-</td>
</tr>
</tbody>
</table>

Omburtamab

This antibody—radioiodinated monoclonal antibody (89Y-PRIMA)—is being developed to target B7-H3-expressing cells in human solid tumors, including embryonal tumors, carcinomas, sarcomas, and brain tumors. In vivo mouse modeling has shown omburtamab binds to an FcRn ligand-dependent conformation on the B7-H3 molecule, enabling it to bind to its ligand function.

Omburtamab is a promising investigational agent for radiolabeled therapy of somatotropinomas metastases, dopamine inhibition, juvenile Glioblastoma (DIPG), and malignant astrocytes.

Navitamab

Neurodegenerative diseases, sarcopenia, and emphysema tumors are difficult to cure when they have metastasized. These cancers include neuroblastomas, melanomas, small-celled lung cancer, brain tumors, osteosarcomas, uveal melanomas, Ewing’s sarcoma, lymphomas, carcinomas, and others. The common tumor antigen on the cell surface of all these tumors is called desmoplastic/leukocyte-G2D. Numerous research laboratories have recently discovered that, in addition, surface G2D is present in different cancer stem cells, microtubules, and metastatic tumor cells.

Our investigational monoclonal antibody has reached clinical trials after Drug Status by the FDA in both neuroblastoma and osteosarcoma, and is currently in a Phase II clinical trial at MSKCC.

G02-G03 Vaccine

Neurodegenerative diseases, including neuroblastomas, sarcopenia, and sarcomas, have a high expression of tumor antigens G02 and G03. Our investigational vaccine G02-G03 vaccine is being studied by scientists at MSKCC for the immunization of high-risk neuroblastoma patients previously treated with nabumetan. The vaccine, in combination with adjuvants, is being studied to induce patients to produce their own anti-G02 and anti-G03 immune filters, with the goal of preventing subsequent relapse. Our investigational G02-G03 vaccine is currently in an ongoing Phase I study at MSKCC.

G02-B04B

To further build upon our investigational anti-G02 immunity, scientists at MSKCC are studying a G02 X G03 isotype antibody (hG02-B04B) with the goal of bringing highly potent T cells to directly kill G02-expressing tumor cells. Our hG02-B04B is the first T cell-engaging antibody utilizing the Bi-specific format to enter human clinical trials. The Bi-specific format utilizes up to four T cell receptors to mediate tumor cell killing and T cell recruitment and differentiation (via a non-receptor, T cell recruitment). In preclinical studies, the hG02-B04B Bi-specific received G02-G03 exclusive potency translation of anti-G02-G03 antibodies. Our investigational hG02-B04B is currently in a Phase IIb study at MSKCC.
Biomarker Testing Site

A responsive site to recruit and educate

Audience: healthcare providers, investors, patients

Designed and developed mobile-first


Confirmed vs. emerging biomarkers

Resources to help you use NGS in your practice

Register for updates

References
1. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut vestibulum erat sem, sit amet lobortis lorem gravida vitae.
2. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut vestibulum erat sem, sit amet lobortis lorem gravida vitae.
3. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut vestibulum erat sem, sit amet lobortis lorem gravida vitae.
4. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut vestibulum erat sem, sit amet lobortis lorem gravida vitae.
5. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut vestibulum erat sem, sit amet lobortis lorem gravida vitae.
Confirmed vs. emerging biomarkers

Resources to help you use NGS in your practice

Register for updates

References
1. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut vestibulum erat sem, sit amet lobortis lorem gravida vitae.
2. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut vestibulum erat sem, sit amet lobortis lorem gravida vitae.
3. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut vestibulum erat sem, sit amet lobortis lorem gravida vitae.
4. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut vestibulum erat sem, sit amet lobortis lorem gravida vitae.
5. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut vestibulum erat sem, sit amet lobortis lorem gravida vitae.

© 2019 Blueprint Medicines Corporation. All rights reserved. USBP-XXX-XX-XXX
RET: an emerging biomarker of interest in NSCLC

Lorem ipsum dolor sit amet, consectetur adipiscing.


Resources to help you use NGS in your practice

References
1. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut vestibulum erat sem, sit amet lobortis lorem gravida vitae.
2. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut vestibulum erat sem, sit amet lobortis lorem gravida vitae.
3. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut vestibulum erat sem, sit amet lobortis lorem gravida vitae.
4. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut vestibulum erat sem, sit amet lobortis lorem gravida vitae.
5. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut vestibulum erat sem, sit amet lobortis lorem gravida vitae.
Resources to help you use NGS in your practice


References
1. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut vestibulum erat sem, sit amet lobortis lorem gravida vitae.
2. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut vestibulum erat sem, sit amet lobortis lorem gravida vitae.
4. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam ipsum lorem, malesuada vitae ipsum nec, dapibus temporus lorem.
5. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut vestibulum erat sem, sit amet lobortis lorem gravida vitae.
Register for updates
Lorem ipsum dolor sit amet, consectetur adipiscing elit.


Submit

References
1. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut vestibulum erat sem, sit amet lobortis lorem gravida vitae.
2. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut vestibulum erat sem, sit amet lobortis lorem gravida vitae.
3. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut vestibulum erat sem, sit amet lobortis lorem gravida vitae.
4. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut vestibulum erat sem, sit amet lobortis lorem gravida vitae.
5. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut vestibulum erat sem, sit amet lobortis lorem gravida vitae.
Pharma Rep Training Tool

An app with a sort of “drag and drop”-game mentality to train pharmaceutical reps on the resources (print pieces, online sources, video modules, etc.) related to a new drug

Designed for iOS, primarily tablet-based users
Pharma Rep Training App

An app to help train pharmaceutical reps on the resources (print pieces, online sources, video modules, etc.) related to a new drug.

Designed for iOS, primarily tablet-based users.

This Slide:
• Section (Landing) Page

Features:
• Section display
• Section selection
• Tool title (displayed on initial app-load only)
Pharma Rep Training App

An app to help train pharmaceutical reps on the resources (print pieces, online sources, video modules, etc.) related to a new drug

Designed for iOS, primarily tablet-based users

This Slide:
• Subsection Page

Features:
• Subsection options slide to top of screen when section (previous page) is selected
• Subsection display
• Subsection selection
Pharma Rep Training App

An app to help train pharmaceutical reps on the resources (print pieces, online sources, video modules, etc.) related to a new drug

Designed for iOS, primarily tablet-based users

This Slide:

- Subsection Page (cont’d)

Features:

- Subtle highlight when subsection is selected
Pharma Rep Training App

An app to help train pharmaceutical reps on the resources (print pieces, online sources, video modules, etc.) related to a new drug

Designed for iOS, primarily tablet-based users

This Slide:

• Subsection Page (cont’d)

Features:

• Full subsection display & color variations
Pharma Rep Training App

An app to help train pharmaceutical reps on the resources (print pieces, online sources, video modules, etc.) related to a new drug

Designed for iOS, primarily tablet-based users

This Slide:

• Interactive Selection (Incomplete)

Features:

• Activity display
• Activity selection
• Note: Each sales tool, video, etc. represented would have a thumbnail pictured
Pharma Rep Training App

An app to help train pharmaceutical reps on the resources (print pieces, online sources, video modules, etc.) related to a new drug

Designed for iOS, primarily tablet-based users

This Slide:

- Interactive Sales Tool Overview (Collapsed)

Features:

- Sales tool pictured (with title and description below)
- Right tool bar will display on tap or swipe (right to left)
Pharma Rep Training App

An app to help train pharmaceutical reps on the resources (print pieces, online sources, video modules, etc.) related to a new drug.

Designed for iOS, primarily tablet-based users.

This Slide:
- Interactive Sales Tool Overview (Open/Incomplete)

Features:
- Sales tool pictured
- User will drag and drop the key message(s)/purpose(s) that correspond to the selected/displayed sales tool.
**Pharma Rep Training App**

An app to help train pharmaceutical reps on the resources (print pieces, online sources, video modules, etc.) related to a new drug.

Designed for iOS, primarily tablet-based users.

**This Slide:**

- Interactive Sales Tool Overview (Open/Complete)

**Features:**

- Sales tool pictured
- Activity complete and correct when options from the “word bank” snap in place (are not rejected) in the blank spaces
Pharma Rep Training App

An app to help train pharmaceutical reps on the resources (print pieces, online sources, video modules, etc.) related to a new drug.

Designed for iOS, primarily tablet-based users.

This Slide:

- Interactive Selection (Complete)

Features:

- Upon completion, each activity (one per each sales tool, video, etc.) will display a ‘✓’ in each subsection where it appears.
Pharma Rep Training App

An app to help train pharmaceutical reps on the resources (print pieces, online sources, video modules, etc.) related to a new drug.

Designed for iOS, primarily tablet-based users.

This Slide:
- Interactive Selection (Complete)

Features:
- Complete activity – color variations
Pharma Rep Training App

An app to help train pharmaceutical reps on the resources (print pieces, online sources, video modules, etc.) related to a new drug.

Designed for iOS, primarily tablet-based users.

This Slide:
• Interactive Selection (Complete)

Features:
• Complete activity – color variations
Pharma Rep Training App

An app to help train pharmaceutical reps on the resources (print pieces, online sources, video modules, etc.) related to a new drug

Designed for iOS, primarily tablet-based users

This Slide:

• Section Page (Subsection Complete)

Features:

• Completed subsection displayed in a darker shade of the section color

• Number of completed subsections displayed
Pharma Rep Training App

An app to help train pharmaceutical reps on the resources (print pieces, online sources, video modules, etc.) related to a new drug

Designed for iOS, primarily tablet-based users

This Slide:

• Section Page
  (Section Complete)

Features:

• Completed section displayed with a ‘shade’ of the section color

• Number of completed subsections displayed
Pharma Rep Training App

An app to help train pharmaceutical reps on the resources (print pieces, online sources, video modules, etc.) related to a new drug

Designed for iOS, primarily tablet-based users

This Slide:
• Subsection Page (Subsection Complete)

Features:
• Completed subsection displayed with a ‘shade’ of the section color
• Number of completed subsections displayed
Pharma Rep Training App

An app to help train pharmaceutical reps on the resources (print pieces, online sources, video modules, etc.) related to a new drug.

Designed for iOS, primarily tablet-based users.

This Slide:

- Subsection Page
  (Section Complete)

Features:

- Completed section displayed with a ‘shade’ of the section color
- Number of completed subsections displayed
Video Module

An unbranded “video module”-style training app for pharmaceutical representatives and their interactions with doctors (in relation to a new drug or drug group)

Designed for desktop and iOS, primarily tablet-based users
Video Module

An unbranded “video module”-style training app for pharmaceutical representatives and their interactions with doctors (in relation to a new drug or drug group)

Designed for desktop and iOS, primarily tablet-based users

Features:

- Video player with title & video description/details
- Video selection bar with option to display more on swipe or tap (on the arrows)
- Note: Video in player goes to full screen when playing
Video Module

An unbranded “video module”-style training app for pharmaceutical representatives and their interactions with doctors (in relation to a new drug or drug group)

Designed for desktop and iOS, primarily tablet-based users

Features:

• Note: Video titles display on hover (desktop) and when pressing & holding (mobile)